| Product Name | Rimegepant Sulfate - API |
| Product Code | DA-R162-a |
| Chemical name | Rimegepant Sulfate |
| Synonyms | (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Hemisulfate; 1-Piperidinecarboxylic acid, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl ester, Sulfate (2:1); |
| Impurity | NA |
| CAS Number | 1642783-82-1 |
| Alternate CAS # | NA |
| Molecular form | C28H28F2N6O3.1/2H2O4S |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 1167.21 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | metabolites,pharmaceutical standards,intermediates,Fine Chemicals |
| Boiling Point | NA |
| Applications | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache,7 and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines.10 While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
